Clinical trials: Neuroepithelial Tumor
Glioma
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132 mutations.
- Trial name
- NCT03030066
- Testing
- DS-1001b
- Where
- Japan
- Volunteers
- 47 people
- Sponsor
- Daiichi Sankyo
Glioblastoma Multiforme of Brain
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain tumors.
- Trial name
- NCT00003456
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Glioma, Patient Reported Outcome Measures
Validity and Reliability Evaluation of the PRO-CTCAE for Adult-type Diffuse Gliomas Patients in Chinese Population
Given the increasing importance of patient's perspective in adverse events reporting, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) has been proposed as new PRO measures in…
- Conditions
- Glioma, Patient Reported Outcome Measures, Self Report, Adverse Effects
- Trial name
- VERONICA (NCT05486923)
- Where
- 14 sites in China
- Volunteers
- 450 people
- Sponsor
- Huashan Hospital
Malignant Gliomas, Oligodendrogliomas
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in IDH mutated gliomas and IDH wild type gliomas.
- Conditions
- Malignant Gliomas, Oligodendrogliomas, Astrocytomas
- Trial name
- NCT02388659
- Testing
- 3 Tesla scanning
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Texas Southwestern Medical Center
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioma
Multimodal Imaging of Hypoxia in Gliomas
The imaging of cerebral oxygenation is an extremely important tool in understanding the pathophysiology of the tumor and for adaptation of therapies according to hypoxia.
- Trial name
- GLIOXYMAGE (NCT03716986)
- Testing
- MRI Oxygen Saturation Map
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Caen
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
MIBG for Refractory Neuroblastoma and Pheochromocytoma
This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are…
- Trial name
- NCT01850888
- Testing
- 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients…
- Conditions
- Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
- Trial name
- NCT04991870
- Testing
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Olfactory Neuroblastoma
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
The goal of this clinical research study is to learn if zanzalintinib can help to control recurrent/metastatic ONB. The safety of zanzalintinib will also be studied.
- Trial name
- NCT07527169
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
The purpose of this study is to evaluate the clinical benefit and safety of two different Dose-Intense temozolomide regimens（one-week on/one-week off regimen versus continuous dose-intense regimen）in patients with glioblastoma at…
- Trial name
- NCT02330991
- Testing
- Temozolomide
- Volunteers
- 204 people
- Sponsor
- Beijing Sanbo Brain Hospital
Malignant Brain Tumor, Glioma
NeuroPathways Intervention for Brain Tumor Patients
This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis.
- Conditions
- Malignant Brain Tumor, Glioma, Coping Skills
- Trial name
- NCT05976490
- Testing
- Information and Support Intervention, Usual supportive care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
AML (Acute Myeloid Leukemia), Glioma
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
- Conditions
- AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
- Trial name
- NCT07486713
- Testing
- Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rigel Pharmaceuticals
Glioblastoma
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating…
- Trial name
- NCT03223103
- Testing
- Poly-ICLC, Tumor Treating Fields, Peptides
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Adilia Hormigo
Recurrent Glioblastoma, Recurrent Adult Brain Tumor
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery.
- Conditions
- Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
- Trial name
- NCT01814813
- Testing
- HSPPC-96, bevacizumab
- Where
- 417 sites in United States
- Volunteers
- 90 people
- Sponsor
- Alliance for Clinical Trials in Oncology
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astrocytoma, Grade II, Astrocytoma, Grade III
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
Rationale: Standard postoperative treatment of isocitrate dehydrogenase 1/2 mutated grade 2 and 3 glioma (IDHmG) consists of radiotherapy and chemotherapy.
- Conditions
- Astrocytoma, Grade II, Astrocytoma, Grade III, Oligodendroglioma, Oligodendroglioma, Anaplastic
- Trial name
- RIGEL (NCT04304300)
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
The purpose of this research study is to test an experimental treatment method for recurrent or progressive brain tumors in children aged from 0-22 years.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes
- Trial name
- NCT02684071
- Testing
- Intra thecal methotrexate, topotecan, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.